Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6508 in hemodialysis patients with secondary hyperparathyroidism
NCT06434961Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of SHR6508 in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Proportion of Participants whose iPTH decreased by >30% from baseline at 27 weeks. Started Jun 2024; status: completed.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT06434961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434961.